Sirna to Webcast JP Morgan Presentation

Sirna Therapeutics, Inc. (Nasdaq: RNAI), is scheduled to present at the 24th Annual JPMorgan Healthcare Conference on Wednesday, January 11, 2006 at 4:00 p.m. PST. A live audio webcast of the presentation will be available at the Company's web site at www.sirna.com.

Sirna is a clinical-stage biotechnology company developing RNAi-based therapies for serious diseases and conditions, including age- related macular degeneration (AMD), hepatitis B and C, dermatology, asthma, Huntington's disease, diabetes and oncology. Sirna Therapeutics has presented interim Phase 1 clinical trial data for its most advanced compound, Sirna-027, a chemically optimized siRNA targeting the clinically validated vascular endothelial growth factor pathway to treat AMD. Sirna-027, which has been partnered with Allergan, Inc., continues to demonstrate that it is safe and well tolerated with 100% of patients showing visual acuity stabilization after eight weeks from a single injection. In addition, Sirna recently announced that it has selected Sirna-AV34, a systemically delivered, optimized siRNA compound, as its candidate for advancement to human clinical testing against Hepatitis C virus.